metoprolol has been researched along with Huntington Disease in 2 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pridopidine is an oral drug in clinical development for treatment of patients with Huntington's disease." | 1.46 | Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease. ( Hallak, H; Muglia, P; Pastino, G; Rabinovich-Guilatt, L; Spiegelstein, O; Steiner, L, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rabinovich-Guilatt, L | 1 |
| Steiner, L | 1 |
| Hallak, H | 1 |
| Pastino, G | 1 |
| Muglia, P | 1 |
| Spiegelstein, O | 1 |
| Gupta, S | 1 |
| Misra, G | 1 |
| Pant, MC | 1 |
| Seth, PK | 1 |
2 other studies available for metoprolol and Huntington Disease
| Article | Year |
|---|---|
Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease.
Topics: Area Under Curve; Cells, Cultured; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP | 2017 |
Prediction of a new surface binding pocket and evaluation of inhibitors against huntingtin interacting protein 14: an insight using docking studies.
Topics: Acyltransferases; Adaptor Proteins, Signal Transducing; Binding Sites; Enzyme Inhibitors; Fluorodeox | 2011 |